Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
Related Questions
How do you decide between administering or deferring upstream P2Y12 inhibitor treatment until patient is in the lab for NSTEMI or STEMI cases with unknown coronary anatomy?
What has been your approach to percutaneous intervention for calcified nodules and threshold for intervention?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
How do you decide between manual pressure versus opting for a specific vascular closure device at the conclusion of a femoral access case?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
What techniques do you use in the lab to reduce the amount of contrast that needs to be used in patients with CKD?
Would you recommend normal saline for pre- and post-LHC hydration in patients with CKD stage III to IV with reduced LV systolic function, and if so, what is a reasonable amount of volume?
For SVG graft stenting, do you consider routinely embolic protection devices (EPD), and do you factor lesion location (prox vs distal) for decision making?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
